Amgen Inc (AMGN)

227.15
+3.21(+1.43%)
  • Volume:
    876,535
  • Bid/Ask
    227.06/227.21
  • Day's Range
    223.56 - 227.50

AMGN Overview

Prev. Close
227.15
Day's Range
223.56 - 227.5
Revenue
25.42B
Open
225.98
52 wk Range
177.05 - 276.69
EPS
12.31
Volume
876,535
Market Cap
130.99B
Dividend (Yield)
7.04 (3.12%)
Average Volume (3m)
2,464,737
P/E Ratio
18.18
Beta
0.72
1-Year Change
9.55%
Shares Outstanding
577,566,383
Next Earnings Date
Apr. 28, 2021
What is your sentiment on Amgen Inc?
or
Vote to see community's results!

Amgen Inc News

Amgen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellSell
SummaryStrong BuyStrong BuyBuyStrong SellNeutral

Amgen Inc Company Profile

Amgen Inc Company Profile

Employees
23400

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.